Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Major changes in sickle cell disease.

R W Hagar1, E P Vichinsky

  • 1Stanford University, Calif., USA.

Advances in Pediatrics
|August 26, 2000
PubMed
Summary
This summary is machine-generated.

Advances in sickle cell disease (SCD) offer new treatments targeting cellular dysfunction and abnormal coagulation. While therapies like transfusions and stem cell transplants show promise, challenges remain in optimizing patient outcomes and preventing organ damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotypic matching of red blood cells.

Immunohematology·2012
Same author

Hemoglobin Hakkari: an autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene.

Pediatric blood & cancer·2009
Same author

Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.

British journal of haematology·2006
Same author

Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.

Journal of pediatric hematology/oncology·2002
Same author

Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease.

The Journal of pediatrics·2001
Same author

Universal newborn screening for Hb H disease in California.

Genetic testing·2001
Same journal

Two Steps Forward-One Step Back: Keeping Pace with Advances.

Advances in pediatrics·2025
Same journal

Pediatric Lymphadenopathy.

Advances in pediatrics·2025
Same journal

Vascular and Gastrointestinal Access in Children.

Advances in pediatrics·2025
Same journal

The Ouchless Pediatric Emergency Department.

Advances in pediatrics·2025
Same journal

Seizures and Shaking in Newborns and Babies.

Advances in pediatrics·2025
Same journal

Procalcitonin in Pediatric Emergency Medicine.

Advances in pediatrics·2025
See all related articles

Area of Science:

  • Hematology
  • Genetics
  • Molecular Medicine

Background:

  • Sickle cell disease (SCD) presents complex hematologic and non-hematologic abnormalities.
  • Recent clinical, molecular, and genetic research has elucidated new pathophysiologic insights into SCD.
  • There is a growing need for effective therapeutic strategies for SCD patients.

Purpose of the Study:

  • To review current and emerging treatment targets for sickle cell disease.
  • To evaluate the potential benefits and risks of various therapeutic modalities.
  • To discuss future directions in SCD management, including genetic therapies and organ damage prevention.

Main Methods:

  • Review of clinical, molecular, and genetic advances in sickle cell disease research.
  • Analysis of validated treatment targets such as cellular dehydration and abnormal coagulation.

Related Experiment Videos

  • Assessment of outcomes and limitations associated with transfusion therapy and stem cell transplantation.

    • Main Results:

    • Targeting cellular dehydration, sickle hemoglobin, endothelial dysfunction, and coagulation offers therapeutic potential.
    • Transfusion therapy can reduce major SCD symptoms but carries risks of complications.
    • Stem cell transplantation shows promise for select patients, but donor availability and early mortality are concerns.

    Conclusions:

    • Future SCD therapies will likely involve combination and staged approaches tailored to disease severity.
    • Genetic manipulation holds long-term potential for broader patient benefit but requires further development.
    • Prospective evaluation of strategies to prevent organ damage (brain, heart, lungs, kidneys) is crucial.